Vaxcyte (PCVX) Corporate presentation summary

Mission and platform overview

• Aims to engineer high-fidelity vaccines to protect against bacterial diseases globally.

• Utilizes a proprietary cell-free protein synthesis platform (XpressCF) for rapid, flexible, and scalable vaccine development.

• Platform enables site-specific conjugation, allowing for broader-spectrum vaccines and production of challenging antigens.

Pneumococcal conjugate vaccine (PCV) franchise highlights

• VAX-31 is the broadest-spectrum PCV in clinical development, targeting ~95% of invasive pneumococcal disease (IPD) in U.S. adults ≥50.

• VAX-24 and VAX-31 designed to cover more serotypes than current pediatric and adult PCVs, with VAX-31 also targeting historically prevalent strains.

• Phase 3 adult program for VAX-31 includes three studies (OPUS-1, OPUS-2, OPUS-3) with topline data expected in late 2026 and early 2027.

• VAX-31 and VAX-24 use a carrier-sparing, site-specific conjugation approach to minimize immune suppression and maximize immunogenicity.

Market opportunity and adoption drivers

• Global pneumococcal vaccine market is ~$8B, with significant growth expected, especially in adults due to expanded recommendations.

• Broader serotype and disease coverage is the primary driver of market adoption, as confirmed by rapid uptake of higher-valency PCVs.

• VAX-31 and VAX-24 positioned to capture market share by offering superior coverage and immunogenicity.